SC 43 - SupremeCure Pharma

Drug Profile

SC 43 - SupremeCure Pharma

Alternative Names: SC-43

Latest Information Update: 06 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SupremeCure Pharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Protein-tyrosine-phosphatase-non-receptor-type-6-agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Cholangiocarcinoma; Colorectal cancer; Hepatocellular carcinoma

Most Recent Events

  • 06 Mar 2018 SupremeCure Pharma has patent protection for SC 43 in the US, China, Taiwan, Korea, Canada, Australia, New Zealand, South Africa, and Russia (SupremeCure Pharma website, March 2018).
  • 06 Mar 2018 Results from a preclinical studies were released by SupremeCure Pharma before March 2018 (SupremeCure Pharma website, March 2018)
  • 05 Mar 2018 Preclinical trials in Breast cancer in Taiwan (PO) (SupremeCure Pharma pipeline, March 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top